175 related articles for article (PubMed ID: 24272336)
1. Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro.
Wang LH; Ni CW; Lin YZ; Yin L; Jiang CB; Lv CT; Le Y; Lang Y; Zhao CY; Yang K; Jiao BH; Yin J
Tumour Biol; 2014 Feb; 35(2):1157-68. PubMed ID: 24272336
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells.
Bremer E; de Bruyn M; Samplonius DF; Bijma T; ten Cate B; de Leij LF; Helfrich W
J Mol Med (Berl); 2008 Aug; 86(8):909-24. PubMed ID: 18504532
[TBL] [Abstract][Full Text] [Related]
3. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2.
Bremer E; Kuijlen J; Samplonius D; Walczak H; de Leij L; Helfrich W
Int J Cancer; 2004 Mar; 109(2):281-90. PubMed ID: 14750182
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR.
Bremer E; Samplonius DF; van Genne L; Dijkstra MH; Kroesen BJ; de Leij LF; Helfrich W
J Biol Chem; 2005 Mar; 280(11):10025-33. PubMed ID: 15644326
[TBL] [Abstract][Full Text] [Related]
5. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas.
Kuan CT; Srivastava N; McLendon RE; Marasco WA; Zalutsky MR; Bigner DD
Int J Cancer; 2010 Aug; 127(3):598-611. PubMed ID: 19937796
[TBL] [Abstract][Full Text] [Related]
6. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
7. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.
Yan C; Li S; Li Z; Peng H; Yuan X; Jiang L; Zhang Y; Fan D; Hu X; Yang M; Xiong D
Mol Pharm; 2013 Jan; 10(1):142-51. PubMed ID: 23121392
[TBL] [Abstract][Full Text] [Related]
8. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells.
Bremer E; Samplonius D; Kroesen BJ; van Genne L; de Leij L; Helfrich W
Neoplasia; 2004; 6(5):636-45. PubMed ID: 15548373
[TBL] [Abstract][Full Text] [Related]
9. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
10. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
[TBL] [Abstract][Full Text] [Related]
11. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
12. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Stieglmaier J; Bremer E; Kellner C; Liebig TM; ten Cate B; Peipp M; Schulze-Koops H; Pfeiffer M; Bühring HJ; Greil J; Oduncu F; Emmerich B; Fey GH; Helfrich W
Cancer Immunol Immunother; 2008 Feb; 57(2):233-46. PubMed ID: 17665197
[TBL] [Abstract][Full Text] [Related]
13. Construction and expression of sTRAIL-melittin combining enhanced anticancer activity with antibacterial activity in Escherichia coli.
Liu H; Han Y; Fu H; Liu M; Wu J; Chen X; Zhang S; Chen Y
Appl Microbiol Biotechnol; 2013 Apr; 97(7):2877-84. PubMed ID: 23149754
[TBL] [Abstract][Full Text] [Related]
14. Review: on TRAIL for malignant glioma therapy?
Kuijlen JM; Bremer E; Mooij JJ; den Dunnen WF; Helfrich W
Neuropathol Appl Neurobiol; 2010 Apr; 36(3):168-82. PubMed ID: 20102513
[TBL] [Abstract][Full Text] [Related]
15. Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.
Yang L; Guo J; Wang J; Wan S; Yang S; Wang R; Chen W; Peng G; Fang D
Int Immunopharmacol; 2012 May; 13(1):37-45. PubMed ID: 22406047
[TBL] [Abstract][Full Text] [Related]
16. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein.
Bremer E; van Dam GM; de Bruyn M; van Riezen M; Dijkstra M; Kamps G; Helfrich W; Haisma H
Mol Ther; 2008 Dec; 16(12):1919-26. PubMed ID: 18813279
[TBL] [Abstract][Full Text] [Related]
17. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
18. CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.
El-Mesery M; Trebing J; Schäfer V; Weisenberger D; Siegmund D; Wajant H
Cell Death Dis; 2013 Nov; 4(11):e916. PubMed ID: 24232092
[TBL] [Abstract][Full Text] [Related]
19. The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma.
Ozyerli-Goknar E; Sur-Erdem I; Seker F; Cingöz A; Kayabolen A; Kahya-Yesil Z; Uyulur F; Gezen M; Tolay N; Erman B; Gönen M; Dunford J; Oppermann U; Bagci-Onder T
Cell Death Dis; 2019 Nov; 10(12):894. PubMed ID: 31772153
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery.
Jiang X; Fitch S; Wang C; Wilson C; Li J; Grant GA; Yang F
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13857-13862. PubMed ID: 27849590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
